{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:58Z","timestamp":1781632378626,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Familial Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The purpose of this study was to estimate the consensus of Australian Health Professionals and\/or Researchers (HP\/Rs) and Consumers (patients\/family\/carers) (Cs) on international genetic testing recommendations. Modified Delphi Panel study with seven domains of interest. Fifty-five statements were devised for an online survey administered in REDCap. HP\/Rs and Cs were recruited from professional networks and associations for participation in the study. Statements were rated using a Likert scale and analysed using descriptive statistics. Free text comments were allowed within each domain and analysed using thematic analysis. Thirty-six HP\/Rs and 27 Cs participated. There was consensus on testing men with a family history of a high-risk hereditary gene; men with PCa and a family history of Hereditary Breast and Ovarian Cancer (HBOC) syndrome or Lynch syndrome; and men with metastatic PCa. There was consensus on testing\u00a0\n                    <jats:italic>BRCA2, BRCA1<\/jats:italic>\n                    and\n                    <jats:italic>DNA MMR<\/jats:italic>\n                    \u00a0genes for men with metastatic PCa. Thematic analysis of HP\/R comments revealed three main topics: the lack of information to make a decision, insufficient knowledge of genetic testing, and capacity to provide genetic testing and counselling. This is the first Australian study on genetic testing recommendations\u00a0in PCa to inform who should be tested and how. Our study showed apparent deficits in knowledge and implementation, exacerbated by workforce issues around the provision of genetic counselling and testing. Future work should focus on evaluating these recommendations for implementation in Australian practice.\n                  <\/jats:p>","DOI":"10.1007\/s10689-025-00528-x","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:11:16Z","timestamp":1769235076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Delphi panel consensus on genetic testing for prostate cancer in Australia: Whom to test and how?"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7379-1294","authenticated-orcid":false,"given":"Kim","family":"Edmunds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3098-4584","authenticated-orcid":false,"given":"Shiksha","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2818-840X","authenticated-orcid":false,"given":"Sri","family":"Teppala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5931-642X","authenticated-orcid":false,"given":"Paul","family":"Scuffham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9186-3972","authenticated-orcid":false,"given":"David","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0552-7402","authenticated-orcid":false,"given":"Matthew J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6842-9223","authenticated-orcid":false,"given":"Lisa","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1474-3214","authenticated-orcid":false,"given":"David P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-3480","authenticated-orcid":false,"given":"Haitham","family":"Tuffaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"528_CR1","unstructured":"Australian Institute of Health and Welfare (AIHW), Cancer data in Australia. 2024, AIHW: Canberra."},{"key":"528_CR2","unstructured":"Australian Institute of Health and Welfare (AIHW), Health system spending on disease and injury in Australia 2022\u20132023. 2024, AIHW: Canberra."},{"key":"528_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00609-3","author":"F Marino","year":"2022","unstructured":"Marino F et al (2022) Germline mutations in prostate cancer: a systematic review of the evidence for personalised medicine. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-022-00609-3","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"528_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","volume":"5","author":"P Nicolosi","year":"2019","unstructured":"Nicolosi P et al (2019) Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol 5(4):523\u2013528","journal-title":"JAMA Oncol"},{"issue":"1","key":"528_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41698-022-00282-8","volume":"6","author":"A Finch","year":"2022","unstructured":"Finch A et al (2022) An appraisal of genetic testing for prostate cancer susceptibility. NPJ Precis Oncol 6(1):43","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"528_CR6","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"C Pritchard","year":"2016","unstructured":"Pritchard C et al (2016) Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 375(5):443\u2013453","journal-title":"N Engl J Med"},{"key":"528_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073753","author":"MT Vietri","year":"2021","unstructured":"Vietri MT et al (2021) Hereditary prostate cancer: genes related, target therapy and prevention. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22073753","journal-title":"Int J Mol Sci"},{"key":"528_CR8","first-page":"1","volume":"13","author":"J Ellison","year":"2022","unstructured":"Ellison J et al (2022) Prostate cancer trteatment costs increase more rapidly than for any other cancer: How to reverse the trend? EPMA J 13:1\u20137","journal-title":"EPMA J"},{"issue":"4","key":"528_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41391-023-00676-0","volume":"27","author":"H Tuffaha","year":"2023","unstructured":"Tuffaha H et al (2023) Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer Prostatic Dis 27(4):594\u2013603","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"528_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mex.2021.101401","author":"D Beiderbeck","year":"2021","unstructured":"Beiderbeck D et al (2021) Preparing, conducting, and analyzing Delphi surveys: cross-disciplinary practices, new directions, and advancements. MethodsX. https:\/\/doi.org\/10.1016\/j.mex.2021.101401","journal-title":"MethodsX"},{"issue":"4","key":"528_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.5662\/wjm.v11.i4.116","volume":"11","author":"P Nasa","year":"2021","unstructured":"Nasa P, Jain R, Juneja D (2021) Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol 11(4):116\u2013129","journal-title":"World J Methodol"},{"issue":"5","key":"528_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/GIM.0b013e31819b2425","volume":"11","author":"JN Harris","year":"2009","unstructured":"Harris JN et al (2009) Interest in genetic testing among affected men from hereditary prostate cancer families and their unaffected male relatives. Genet Med 11(5):344\u2013355","journal-title":"Genet Med"},{"key":"528_CR13","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"P Harris","year":"2019","unstructured":"Harris P et al (2019) The REDCap consortium: building an international community of software partners. J Biomed Inform 95:103208","journal-title":"J Biomed Inform"},{"issue":"4","key":"528_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","volume":"67","author":"I Diamond","year":"2014","unstructured":"Diamond I et al (2014) Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol 67(4):401\u2013409","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"528_CR15","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.techfore.2012.04.013","volume":"79","author":"H von der Gracht","year":"2012","unstructured":"von der Gracht H (2012) Consensus measurement in Delphi studies: review and implications for future quality assurance. Technol Forecasting Soc change. 79(8):1525\u20131536","journal-title":"Technol Forecasting Soc change."},{"issue":"8","key":"528_CR16","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1080\/0142159X.2020.1755030","volume":"42","author":"M Kiger","year":"2020","unstructured":"Kiger M, Varpio L (2020) Thematic analysis of qualitative data: AMEE guide 131. Med Teach 42(8):846\u2013854","journal-title":"Med Teach"},{"issue":"2","key":"528_CR17","first-page":"e204","volume":"17","author":"T Scheinberg","year":"2020","unstructured":"Scheinberg T et al (2020) Evaluation of a mainstream model of genetic testing for men with prostate cancer. J Clin Oncol 17(2):e204-216","journal-title":"J Clin Oncol"},{"issue":"6","key":"528_CR18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO-24-02608","volume":"43","author":"E Yu","year":"2025","unstructured":"Yu E et al (2025) Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline. J Clin Oncol 43(6):748\u2013758","journal-title":"J Clin Oncol"},{"key":"528_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.14150","author":"A Azad","year":"2025","unstructured":"Azad A et al (2025) BRCA mutation testing in men with metastatic castration-resistant prostate cancer: practical guidance for Australian clinical practice. Asia Pac J Clin Oncol. https:\/\/doi.org\/10.1111\/ajco.14150","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"528_CR20","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1200\/OP-24-00626","volume":"21","author":"N Shore","year":"2024","unstructured":"Shore N (2024) Implementation of universal germline genetic testing into standard of care for patients with prostate cancer: the time is now. JCO Oncol Pract 21(6):747\u2013753","journal-title":"JCO Oncol Pract"},{"issue":"24","key":"528_CR21","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.20.00046","volume":"38","author":"VN Giri","year":"2020","unstructured":"Giri VN et al (2020) Implementation of germline testing for prostate cancer: Philadelphia prostate cancer consensus conference 2019. J Clin Oncol 38(24):2798\u20132811","journal-title":"J Clin Oncol"},{"key":"528_CR22","unstructured":"National Comprehensive Cancer Network (NCCN) (2022) NCCN clinical practice guidelines in oncology. Prostate cancer, Version 4.2022."},{"issue":"3","key":"528_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100459","volume":"7","author":"A Russo","year":"2022","unstructured":"Russo A et al (2022) Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian scientific societies. ESMO Open 7(3):100459","journal-title":"ESMO Open"},{"key":"528_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.962958","volume":"12","author":"PKF Chiu","year":"2022","unstructured":"Chiu PKF et al (2022) Genetic testing and its clinical application in prostate cancer management: consensus statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology. Front Oncol 12:962958","journal-title":"Front Oncol"},{"issue":"1","key":"528_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"J Eastham","year":"2022","unstructured":"Eastham J et al (2022) Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol 208(1):10\u201318","journal-title":"J Urol"},{"issue":"4","key":"528_CR26","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","volume":"77","author":"S Gillessen","year":"2020","unstructured":"Gillessen S et al (2020) Management of patients with advanced prostate cancer: Report of the advanced prostate cancer consensus conference 2019. Eur Urol 77(4):508\u2013547","journal-title":"Eur Urol"},{"issue":"2","key":"528_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","volume":"73","author":"S Gillessen","year":"2018","unstructured":"Gillessen S et al (2018) Management of patients with advanced prostate cancer: The report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73(2):178\u2013211","journal-title":"Eur Urol"},{"issue":"5","key":"528_CR28","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s12094-021-02561-5","volume":"23","author":"A del Gonz\u00e1lez Alba","year":"2021","unstructured":"del Gonz\u00e1lez Alba A et al (2021) SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). Clin Transl Oncol 23(5):969\u2013979","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"528_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/JU.0000000000001375","volume":"205","author":"W Lowrance","year":"2021","unstructured":"Lowrance W et al (2021) Advanced prostate cancer: AUA\/ASTRO\/SUO guideline part I. J Urol 205(1):14\u201321","journal-title":"J Urol"},{"issue":"1","key":"528_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/JU.0000000000001376","volume":"205","author":"WT Lowrance","year":"2021","unstructured":"Lowrance WT et al (2021) Advanced prostate cancer: AUA\/ASTRO\/SUO guideline part II. J Urol 205(1):22\u201329","journal-title":"J Urol"},{"issue":"2","key":"528_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet N et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 79(2):243\u2013262","journal-title":"Eur Urol"},{"issue":"9","key":"528_CR32","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C et al (2020) Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(9):1119\u20131134","journal-title":"Ann Oncol"},{"issue":"4","key":"528_CR33","first-page":"E137","volume":"14","author":"F Saad","year":"2020","unstructured":"Saad F et al (2020) Controversial issues in the management of patients with advanced prostate cancer: results from a Canadian consensus forum. Can Urol Assoc J 14(4):E137-e149","journal-title":"Can Urol Assoc J"},{"issue":"14","key":"528_CR34","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/pros.24053","volume":"80","author":"ND Shore","year":"2020","unstructured":"Shore ND et al (2020) Optimizing the management of castration-resistant prostate cancer patients: a practical guide for clinicians. Prostate 80(14):1159\u20131176","journal-title":"Prostate"},{"key":"528_CR35","doi-asserted-by":"publisher","DOI":"10.4414\/SMW.2021.w30038","volume":"151","author":"S Stoll","year":"2021","unstructured":"Stoll S et al (2021) Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer. Swiss Med Wkly 151:w30038","journal-title":"Swiss Med Wkly"},{"key":"528_CR36","doi-asserted-by":"publisher","DOI":"10.1080\/21681805.2022.2094462","author":"O Bratt","year":"2022","unstructured":"Bratt O et al (2022) The swedish national guidelines on prostate cancer, part 1: early detection, diagnostics, staging, patient support and primary management of non-metastatic disease. Scand J Urol. https:\/\/doi.org\/10.1080\/21681805.2022.2094462","journal-title":"Scand J Urol"},{"issue":"4","key":"528_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/21681805.2022.2093396","volume":"56","author":"O Bratt","year":"2022","unstructured":"Bratt O et al (2022) The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castrate resistant disease. Scand J Urol 56(4):278\u2013284","journal-title":"Scand J Urol"},{"key":"528_CR38","unstructured":"Cancer Institute NSW. Prostate Cancer - Panel testing 3648 v.3. 2020; Available from: https:\/\/www.eviq.org.au\/cancer-genetics\/adult\/risk-management\/656-brca1-or-brca2-risk-management-male."},{"issue":"12s","key":"528_CR39","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/S1166-7087(20)30752-1","volume":"30","author":"F Rozet","year":"2020","unstructured":"Rozet F et al (2020) Cancer committee of the French association of urology guidelines\u2014update 2020\u20132022: prostate cancer. Prog Urol 30(12s):S136-s251","journal-title":"Prog Urol"},{"key":"528_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2024.101270","author":"A Smit","year":"2024","unstructured":"Smit A et al (2024) Ethical, legal, and social issues related to genetics and genomics in cancer: a scoping review and narrative synthesis. Genet Med. https:\/\/doi.org\/10.1016\/j.gim.2024.101270","journal-title":"Genet Med"},{"key":"528_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/op-24-00624","author":"L Beidler","year":"2025","unstructured":"Beidler L et al (2025) Perceptions and use of germline genetic testing among patients with prostate cancer. JCO Oncol Pract. https:\/\/doi.org\/10.1200\/op-24-00624","journal-title":"JCO Oncol Pract"},{"issue":"19","key":"528_CR42","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1001\/jama.2015.14905","volume":"14","author":"A Jemal","year":"2015","unstructured":"Jemal A et al (2015) Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 14(19):2054\u20132061","journal-title":"JAMA"},{"key":"528_CR43","unstructured":"Cancer Australia. Prostate cancer in Australia statistics. 2024 [cited 2024 August 29, 2024]; Available from: https:\/\/www.canceraustralia.gov.au\/cancer-types\/prostate-cancer\/statistics."},{"key":"528_CR44","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.euros.2024.07.113","volume":"71","author":"C Gratzke","year":"2025","unstructured":"Gratzke C et al (2025) A cross-sectional survey of physicians to understand biomarker testing and treatment patterns in patients with prostate cancer in the USA, EU5, Japan, and China. Eur Urol Open Sci 71:148\u2013155","journal-title":"Eur Urol Open Sci"},{"key":"528_CR45","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2152233","author":"S Teppala","year":"2023","unstructured":"Teppala S et al (2023) A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. J Med Econ. https:\/\/doi.org\/10.1080\/13696998.2022.2152233","journal-title":"J Med Econ"},{"issue":"11","key":"528_CR46","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.jval.2024.06.019","volume":"27","author":"S Teppala","year":"2024","unstructured":"Teppala S et al (2024) The cost-effectiveness of germline BReast CAncer gene testing in metastatic prostate cancer followed by cascade testing of first-degree relatives of mutation carriers. Value Health 27(11):1515\u20131527","journal-title":"Value Health"},{"key":"528_CR47","doi-asserted-by":"crossref","unstructured":"Teppala S et al (2025) The cost-utility of targeted germline BRCA testing in localised prostate cancer followed by cascade testing first-degree relatives with pathogenic variants. Genetics in Medicine","DOI":"10.1016\/j.gim.2025.101463"}],"container-title":["Familial Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00528-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10689-025-00528-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10689-025-00528-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:04:12Z","timestamp":1781629452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10689-025-00528-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["528"],"URL":"https:\/\/doi.org\/10.1007\/s10689-025-00528-x","relation":{},"ISSN":["1573-7292"],"issn-type":[{"value":"1573-7292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare they have no conflict of interest in relation to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. Ethical approval was granted by the Health and Behavioural Science Research Committee at the University of Queensland (2022\/HE001998).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants received information statements and consented to participate in the study. No participants were identified in this publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"12"}}